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Protocol
ABSTRACT
Introduction Around 30% of peripherally inserted 
central catheters (PICCs) fail from vascular, infectious 
or mechanical complications. Patients with cancer are 
at highest risk, and this increases morbidity, mortality 
and costs. Effective PICC dressing and securement may 
prevent PICC failure; however, no large randomised 
controlled trial (RCT) has compared alternative 
approaches. We designed this RCT to assess the clinical 
and cost-effectiveness of dressing and securements to 
prevent PICC failure.
Methods and analysis Pragmatic, multicentre, 
2×2 factorial, superiority RCT of (1) dressings 
(chlorhexidine gluconate disc (CHG) vs no disc) and (2) 
securements (integrated securement dressing (ISD) 
vs securement device (SED)). A qualitative evaluation 
using a knowledge translation framework is included. 
Recruitment of 1240 patients will occur over 3 years 
with allocation concealment until randomisation by a 
centralised service. For the dressing hypothesis, we 
hypothesise CHG discs will reduce catheter-associated 
bloodstream infection (CABSI) compared with no CHG 
disc. For the securement hypothesis, we hypothesise that 
ISD will reduce composite PICC failure (infection (CABSI/
local infection), occlusion, dislodgement or thrombosis), 
compared with SED. Secondary outcomes: types of PICC 
failure; safety; costs; dressing/securement failure; dwell 
time; microbial colonisation; reversible PICC complications 
and consumer acceptability. Relative incidence rates of 
CABSI and PICC failure/100 devices and/1000 PICC days 
(with 95% CIs) will summarise treatment impact. Kaplan-
Meier survival curves (and log rank Mantel-Haenszel test) 
will compare outcomes over time. Secondary end points 
will be compared between groups using parametric/non-
parametric techniques; p values <0.05 will be considered 
to be statistically significant.
Ethics and dissemination Ethical approval from 
Queensland Health (HREC/15/QRCH/241) and Griffith 
University (Ref. No. 2016/063). Results will be published.
Trial registration Trial registration number is: 
ACTRN12616000315415.
InTroducTIon
Peripherally inserted central catheters 
(PICCs) are commonly placed in patients 
with cancer for anticancer therapies, other 
medicines, fluids, nutrition blood products 
Strengths and limitations of this study
 ► This is the first large-scale, independent multicentre 
randomised controlled trial to investigate the efficacy 
and cost-effectiveness of peripherally inserted 
central catheters  (PICC) dressing and securement 
methods in adult and paediatric cancer populations 
to prevent PICC complications.
 ► This is a pragmatic trial, with PICCs inserted 
and cared for by general staff in three hospitals 
using existing protocols, not specialist teams or 
researchers.
 ► Microbiology end points will be analysed by blinded 
scientists, and infection outcomes assigned by 
a blinded infectious disease specialist outcome 
assessor.
 ► Dressing and securement interventions cannot be 
blinded to clinical staff, patients or research nurses.
 ► Patients with existing diseased and/or non-clipped 
hirsute skin at the insertion point are excluded from 
the study so results will not be generalisable to 
these groups.
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and for frequent blood sampling. Although initially 
viewed as safer, cheaper and more durable than centrally 
inserted venous catheters,1 2 approximately 30% of PICCs 
fail before completion of treatment from complications, 
with prevalence highest in patients with cancer.3–8 As most 
cancer treatment is in ambulatory (outpatient) settings, 
PICC failure interrupting treatment poses substantial 
increases in lost outpatient booking times. It also depletes 
patients’ useable veins for future treatment and can 
obstruct vessels long-term. Moreover, delays to chemo-
therapy cycles reduce treatment efficacy and can affect 
subsequent survival.9
PICC failure can be from infective, vascular or mechan-
ical complications. Infections can be local insertion site 
infections which occur in 1% of PICCs in patients with 
cancer,10 or catheter-associated bloodstream infection 
(CABSIs) experienced by 7% hospitalised patients with 
cancer with PICCs,11 which increases mortality almost 
threefold.12 Vascular complications occur via PICC 
damage to the vessel endothelium, which may present 
as deep venous thrombosis (DVT) with severe pain and 
swelling, risk of thrombus detachment and potentially 
devastating pulmonary embolism.1 Patients with cancer 
frequently have increased DVT risk from coagulopathy or 
other haematological imbalances, and a recent meta-anal-
ysis reported DVT in 7% of those with PICCs.13
Mechanical complications include partial or total 
dislodgement from the vein, occurring in 5%–13% of 
PICCs,3 5 6 8 via ‘drag’ from multiple infusion tubes, or 
‘catching’ on environmental structures (eg, clothing, 
chairs).14 15 Partial dislodgement malpositions the cath-
eter tip which can cause infiltration of irritant infusion 
fluids and medication into tissue causing injury and 
potentially necrosis.16 Occlusion can result from build-up 
of blood or infusion products inside the PICC, or PICC 
compression by an irritated, swollen vein wall. Clinicians 
may fracture the PICC through excessive force when 
attempting to clear occlusion. Occlusion, with or without 
fracture, occurs in 4%–23% of PICCs.3 5 6 8
It is projected that 7.2 million PICCs will be sold in the 
USA alone in 2017, with revenue of US$1.26 billion.17 
Significant numbers are used worldwide, and the high 
incidence of PICC failure imposes substantial burden 
on patients and the health system. CABSI alone costs 
between US$12 000 and US$68 000 (2011) per episode, 
and 21 additional hospital days.18–20 Troubleshooting, 
including PICC salvage, and replacement of failed PICCs 
further increases costs.
current standard care for PIcc dressing and securement
Interventions to prevent PICC complications include: (i) 
dressings on the insertion site to prevent microbial entry 
and infection and (ii) securement to the skin to prevent 
gross dislodgement and micromotion (‘pistoning’, which 
potentiates DVT, occlusion and infection).21 Standard 
polyurethane (SP) transparent dressings with acrylic 
adhesive have been usual care since the 1980s.22 23 A 
Cochrane review (7436 patients with central catheters, 
including 270 PICCs) found 6% CABSI and 9% dislodge-
ment associated with SP dressings.15
Traditionally, PICCs were sutured for securement but 
securement devices (SEDs) are now preferred to avoid 
staff needlestick injury and PICC site infections.23 SEDs 
have a large adhesive padded footplate with a device-
locking clasp to reduce movement, kinking and flow 
impedance.24 The one randomised controlled trial 
(RCT) published on SEDs reported similar dislodgement 
compared with sutures (12% vs 14%), but significantly 
reduced CABSI (2% vs 12%, p<0.01).3 This single-centre 
trial studied 170 adult patients including only 32 patients 
with cancer, and the inclusion and exclusion criteria 
were unclear. SPU were replaced every 3 days in both 
groups while in hospital, standard practice at that time, 
but different to current 5–7 days replacement policies.23 
The Cochrane review concluded there was inadequate 
information on generation of randomisation, attrition 
and noted SED manufacturer funding; they concluded 
further research was required,25 but this has not occurred.
novel solutions for PIcc dressing and securement
Chlorhexidine gluconate (CHG) discs placed under SP 
dressings release antiseptic around the PICC entry site for 
up to 10 days.21 26 Systematic reviews have demonstrated 
effectiveness in CABSI prevention for central venous 
catheters, but not PICCs.21 26–28 In patients with cancer, 
a single central venous catheter (CVC) trial is available, 
which reported lower CABSI with CHG discs than SP 
alone (6% vs 11%, p=0.02).29 The skin of patients with 
cancer is often impaired from steroid, radiation and/or 
chemotherapy treatment,30 and CHG may further irri-
tate or damage skin.31 32 There are also concerns about 
potential antimicrobial resistance, allergic reactions and 
systemic absorption in neonates, which may be limiting 
uptake.26 33
Integrated securement dressings (ISDs) are ‘next-gen-
eration’ SP dressings designed to replace both SP and 
SED. They have a tough fabric adhesive border, a second 
adhesive component that holds the PICC from beneath, 
and can be used with or without a CHG disc. A recent 
cohort study in PICCs (n=421) compared ISDs with histor-
ical SP+suture controls, finding ISDs associated with less 
CABSI (6% vs 11%, p=0.13), dislodgement (4% vs 6%, 
p=0.27) and overall PICC failure (21% vs 25%, p=0.54).34 
Occlusion in ISD-secured PICCs occurred significantly 
later, at 25 vs 8 days (p<0.01).34 Despite these promising 
findings, ISDs have not yet been tested in an RCT.
Cost-effectiveness analysis is lacking from the literature 
for PICC dressing and securement products, and data are 
needed to resolve this uncertainty. With millions of PICCs 
used globally,17 even small differences in cost-effectiveness 
could significantly reduce hospital budgets. For example, 
introduction of CHG discs for intensive care unit CVCs, 
saw net annual savings in the USA of US$275 million to 
US$2 billion for CABSI treatment.35–37
We designed a pragmatic clinical trial that has three 
main objectives:
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1. To compare the effectiveness of PICC dressing with 
(i) a CHG disc and (ii) no CHG disc to prevent CABSI 
and adverse events;
2. To compare the effectiveness of securement with (i) 
an SED and (ii) an ISD to prevent PICC failure and 
adverse events;
3. To evaluate the acceptability of ISD and CHG discs to 
patients and healthcare professionals, and to identify 
barriers, enablers and strategies for translation of 
results into policy and practice.
MeThods and analysIs
This pragmatic, multicentre, 2×2 factorial, superiority 
RCT will test the clinical efficacy and cost-effectiveness 
of (1) dressings (CHG disc vs no disc) and (2) secure-
ments (SD vs ISD) (table 1). Embedded in the RCT is 
a formative, qualitative evaluation38 of trial products and 
processes using a knowledge translation framework.39
hypotheses
Dressing hypothesis
1. The use of a CHG disc will reduce the incidence of 
PICC CABSI compared with the use of no disc.
Securement hypothesis
1. The use of an ISD will reduce the incidence of 
composite PICC failure, compared with the use of 
SED.
sample size and study power
Dressing hypothesis
Our baseline CABSI is 8% with no CHG disc and we 
predict this incidence in the combined no CHG disc 
group. We expect 4% CABSI in the combined CHG disc 
groups, based on a risk ratio (RR) of 0.52 previously asso-
ciated with CHG discs (n=7436).21 A one-sided inequality 
test of two proportions calculated that 602 PICCs per 
group would detect reduced CABSI incidence from 8% to 
4% with 90% power (p=0.05, Power Analysis and Sample 
Size software [PASS]) (602 CHG disc; 602 no CHG disc).
To test the securement hypothesis
Our local baseline PICC failure is 26% with SED and we 
predict this for the combined SED groups. We hypothe-
sise 19% failure in the combined ISD groups (RR=0.73 
as the midpoint between RR=0.84 associated with ISD 
vs SP+sutures in PICCs,34 and the pooled RR=0.63 seen 
in our pilot trials).40–42 A one-sided inequality test of two 
proportions calculated that 608 PICCs per group (608 
ISD; 608 SED) could compare 26% and 19% PICC failure 
with 90% power (p=0.05, PASS).
Because of the factorial design, we used the comparison 
that required the larger sample (608 per group), plus 
2% for potential attrition, thus 620 per group (total trial 
1240). This was split so that each of the four study groups 
had 310 PICCs. We assumed no interaction effect between 
the interventions, but tested this in a Cox proportional 
hazards model, and analysed CHG disc effect (vs no disc) 
and the ISD effect (vs SED) separately (at the margins) 
using similar techniques.27 43 A Data Safety Monitoring 
Committee reviewed blinded data and serious adverse 
events at n=400 and n=800 to advise on (i) sample size 
adjustments or (ii) study stopping for efficacy in one or 
more arms (multiplicity adjustment, p<0.017) or if one 
or more arms should be stopped due to futility.44 45 This 
advice was reviewed by CMR, NM, JW, MM and VC, who 
made the final decision to terminate the trial.
setting and sample
After ethical, legal and governance approvals, adult 
and paediatric patients were recruited at three hospi-
tals in Queensland, Australia (Lady Cilento Children’s 
Hospital; Princess Alexandra Hospital and Royal Bris-
bane and Women’s Hospital). Inclusion criteria were: 
haematological malignancy or solid tumour diagnosis; 
PICC required >24 hours and patient/parent gave 
informed consent. Exclusion criteria were: non-central 
PICC tip placement at baseline (eg, tip in subclavian/
brachiocephalic/jugular vein); current BSI (<48 hours); 
PICCs inserted through diseased or hirsute skin; allergy 
to any study product; PICCs did not already had a CHG 
disc/dressing in place. Once a patient entered the trial, 
consecutive PICCs were studied (as long as the inclu-
sion/exclusion criteria were met), with all PICCs per 
patient following the same randomisation allocation. 
To ensure generalisability, PICCs inserted after-hours 
were also studied if these additional criteria were met: 
(i) <24 hours since PICC insertion; (ii) no compromise 
in PICC function; (iii) predicted further use ≥24 hours; 
(iv) the treating clinician agreed it was safe to replace the 
initial dressing/securement.
outcome measures and definitions
Dressing hypothesis
Primary outcome
The primary outcome was CABSI: a laboratory confirmed 
BSI (LCBSI 1; LCBSI 2 or LCBSI 3) that is not secondary 
to an infection at another body site (eg, mucosal barrier 
Table 1 Four groups within factorial randomised controlled trial
 2×2 factorial Securement: SED (control) Securement: ISD
Dressing: no CHG disc (control) SD+SP, no CHG disc ISD, no CHG disc
Dressing: CHG disc SD+SP with CHG disc ISD with CHG disc
CHG, chlorhexidine gluconate; ISD, integrated securement dressing; SD, securement dressing; SED, securement device; SP, standard 
polyurethane.
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injury LCBSI), with PICC in place for >2 calendar days on 
the day of the BSI (day of PICC placement being day 1), 
and the PICC was in place on the date of the event or the 
day before, when all elements of LCBSI, were first present 
together (see CDC National Healthcare Safety Network 
for full criteria),46 confirmed by a blinded infectious 
disease specialist using de-identified data.
securement hypothesis
The primary outcome was PICC failure (composite of 
infection, occlusion, dislodgement, thrombosis) for the 
securement hypothesis.
 ► Infection
 ► CABSI: as above, or,
 ► Local infection (exit-site infection): microbiological 
diagnosis—purulent discharge (microorganism 
identified from exudate); or, clinical diagnosis—
erythema, induration and/or tenderness within 
2 cm of PICC exit site and may be associated with 
other signs and symptoms of infection such as 
fever or purulent drainage; BOTH with or without 
concomitant bloodstream infection,47 confirmed 
by a blinded infectious disease specialist.
 ► Occlusion
 ► Occlusion: ≥1 lumens cannot be flushed, 
aspirated or resolved post-thrombolytic dwell,3 or
 ► Fracture: visible split in PICC material with 
leakage or radiographic evidence of extravasation 
or infiltration into tissue, causing removal.6
 ► Dislodgement
 ► Partial: change in PICC length from baseline 
measurement closest to skin site or PICC 
removal due to development of tip malposition 
(diagnosed radiographically and/or by site 
leakage on injection and/or infusion), or 
development of non-central tip (eg, isolateral 
jugular or contralateral brachiocephalic, 
diagnosed radiographically),3 or
 ► Complete: PICC body completely leaves the vein.3
 ► Venous thrombosis
 ► Suspected: removed as too painful for patient to 
tolerate,3or
 ► Confirmed: ultrasound-confirmed or venogram-
confirmed thrombosed vessel (brachial, basilica, 
axillary or subclavian) at the PICC site in a 
symptomatic (arm pain, swelling, redness and/
or tenderness over the PICC) patient,3 21 or 
diagnosis by CT, MRI or other imaging, or a 
symptomatic patient with a thrombus or fibrin 
sheath occluding ≥1 lumen at PICC removal.10
secondary outcomes (for both the dressing and securement 
hypotheses)
 ► Types of PICC failure: each failure type (local infection/
CABSI, occlusion, dislodgement or thrombosis), 
in addition to PICC-related bloodstream infection 
(laboratory confirmed matched organism from blood 
and catheter tip, or differential time to positivity).22 46 47
 ► Safety end points: skin rash, skin tears, blisters, pruritus, 
local or systemic allergic reactions.
 ► Costs: direct costs to the hospital (in AUD) for the 
total episode of care, including costs of device and 
dressing replacement plus cost of treating PICC 
complications.
 ► Dressing/securement failure: replacement before 7 
days for loose, missing, bloodstained, diaphoresis or 
secretion-soaked dressings/SEDs (dichotomous).48
 ► PICC and dressing/securement dwell time: hours from 
insertion/application until removal.40
 ► Device/skin site colonisation: >15 cfu growth from skin 
swab taken from PICC entry site, or PICC tip culture 
after removal.47
 ► Patient/parent and staff acceptability: 0–10 numerical 
rating scales.41
 ► Relative PICC failure in experimental groups: the 
2×2 experimental groups were compared.
 ► Reversible PICC complications: complications (eg, 
occlusion, infection, fracture, internal malposition) 
that did not cause PICC failure, but required an 
intervention (eg, urokinase, alteplase, ethanol, 
PICC mended, warmed saline, reposition or ‘pop’ 
technique).
recruitment, randomisation, allocation concealment and 
blinding
Research nurses (ReNs) screened patients, obtained 
consent after a full explanation of the trial and responded 
to any questions, randomised patients, educated clinical 
staff, patients and families, monitored protocol compli-
ance and collected data. Central web-based randomisation 
with allocation concealment was patient level with 1:1:1:1 
ratio between groups (randomly varied block sizes) and 
stratification by: (i) hospital, (ii) cancer type (haema-
tological malignancy or solid tumour), (iii) inpatient/
outpatient status and (iii) previous PICC treatment ever 
(yes/no). Study products were in numbered prepacks 
and ReNs liaised with inserters. It is not possible to blind 
dressing and securements, since clinical staff must apply 
and monitor these, and ReNs must assess protocol compli-
ance. The primary outcomes of CABSI/PICC failure are 
objective, easily and routinely collected by clinical staff 
(not investigators) in usual practice. Blinded microbiolo-
gists and infectious disease physicians assigned infection 
outcomes. A blinded statistician analysed data.
Insertion and care of the PIcc, dressing and securements
ReNs were not involved in PICC insertion, application 
of study products or PICC care, but provided prestudy 
and intrastudy education to hospital staff, including user 
guides, to promote consistency. PICC inserters used a 
large sterile drape and gown, prepared skin with 2% CHG 
in alcohol22 and select ed insertion site, PICC type and 
approach based on clinical judgement, then applied allo-
cated products. Numbered prepacks of allocated products 
with a usage form was kept at the bedside and monitored 
by the ReNs, who confirmed the timing and reason for 
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replacements and/or reinforcements with nursing staff. 
A protocol violation is ‘the randomised product was never 
used to secure the PICC’. A protocol deviation is if incor-
rect dressing and securements are used for a proportion 
of the PICC dwell. Unless contraindicated (eg, irritation), 
deviations were corrected and the proportion of PICC 
dwelled with deviations, and reasons for these were noted. 
Study products were changed weekly and as needed, with 
sterile gauze used temporarily if sites bled excessively or 
for excessive diaphoresis.22 Use of gauze and tape or addi-
tional products (eg, extra strips of tape, bandage) was 
recorded for proportion of dwell time in use, and reasons 
for use. If CABSI was suspected by treating medical staff, 
percutaneously drawn and CVAD-drawn blood cultures 
were taken, in addition to PICC tip (if removed) culture 
and purulent discharge (if any) culture. PICC removal 
was decided by treating clinical staff as per usual practice, 
with no involvement by investigators.
data collection
The ReNs collected data from electronic and other 
charts, using hand-held devices and a REDCap data-
base (Research Electronic Data CAPture, Vanderbilt). 
The ReNs reinforced the protocol with patients and staff. 
A study manager checked allocation integrity, inter-rater 
reliability for skin and dressing assessments and moni-
tored 100% source data verification for first patient per 
site, consent forms, primary outcomes and a random 5% 
of other data for all patients. Site-specific hospital data at 
3–6 monthly intervals noted any changes in local PICC 
policy or products.
At enrolment, ReNs collected patient demographics 
(eg, age, gender, weight); clinical factors (eg, diagnostic 
group, comorbidities, any infection, neutropaenia, coag-
ulopathy, skin integrity); PICC factors (eg, insertion site, 
inserter discipline, technology-assisted insertion, number 
of insertion attempts, PICC type, size, gauge, emergency 
insertion, side (right/left), insertion department) and 
treatment factors (immunosuppressants, anticancer 
treatment, transfusion, antimicrobials, parenteral nutri-
tion, continuous or intermittent therapy). Clinicians 
rated ease of study product application using an 11-point 
scale (0=very difficult, 10=very easy), and noted previous 
number of applications of that product type.10 21 22 49
The ReNs followed-up study patients daily while in 
hospital, and weekly as outpatients (in clinic or telephone) 
for a maximum of 8 weeks (captured 90% of dwell data), 
or until PICC failure or removal if this occurred earlier. 
Patients contacted study staff at any time if they had ques-
tions or concerns. Each visit, dressing and securements in 
place, and any replacement or addition (with reason and 
timing) was noted. The PICC site was assessed for redness, 
discharge, pain, swelling, skin reactions to study products 
or diaphoresis. Primary, secondary and adverse outcomes 
(eg, skin reactions/injury) and changes in clinical, PICC 
or treatment factors were recorded.
At study completion, data were collected on: all infu-
sates given through the PICC (including any lock 
solutions); patient mobility and cognitive status and 
patient/parent satisfaction with the study products 
(0=completely dissatisfied, 10=completely satisfied). The 
removing nurse rated the difficulty of product removal 
(0=very difficult, 10=very easy), and number of previous 
removals of that product type. The reason for removal was 
recorded, including any complications/failure, and PICC 
dwell time. ReNs prepared blinded microbiological and 
clinical data, and an infectious disease physician assessed 
infection end points. Hospital length of stay and mortality 
were recorded.
Microbiological substudy
A blinded microbiologist compared numbers and type 
of skin bacteria under the dressing/securement prod-
ucts at removal (purposive sample of 31 patients per 
group, n=124). Patients were not able to be selected at 
random, as there were limited opportunities when ReNs 
were available at the time of the dressing replacement; 
however, we collected consecutive samples from 124 
available patients at the Royal Brisbane and Women’s 
Hospital. This ensures samples were collected by a small 
number of research nurses (two) with extensive training 
and audit to standardise sampling methods. Approxi-
mately 2 cm2 of skin at the insertion site was swabbed 
using a sterile cotton swabstick moistened with sterile 
saline for 10 s using back and forward motion and rolling 
motion, then placed in sterile tubes. Swabs and any avail-
able PICC tips were cultured on non-selective agar and 
incubated aerobically at 37°C. Total number of colonies 
were counted and bacteria were identified at 24 hours, 
repeated at 72 hours for slow-growing species.50 Antibi-
otic resistance was tested genetically (qacA/B and smr),51 
and CHG tolerance was tested by minimum inhibitory 
concentrations for each isolate using broth microdilu-
tion.52 Any positive clinical isolates from other body sites 
were noted from hospital records and compared with 
skin swab results. Specimens have been stored for future 
studies of infection prevention, if patients consent to 
this.
Quantitative data analysis
The lead investigator, statistician and study manager 
had access to the final dataset. Analyses and reporting 
followed the Consolidated Standards of reporting 
Trials (CONSORT) Statement. Intention-to-treat anal-
ysis occurred with patients, the unit of randomisation 
and PICCs, the unit of measurement. Outlying figures, 
missing and implausible data were cleaned. Patients who 
withdrew from the intervention requested to allow collec-
tion of the primary end point. Lost to follow-up patients 
had outcome data modelled for best-case and worst-case 
scenarios, with multiple imputations considered if data 
were missing at random. A per-protocol analysis assessed 
the effect of withdrawn or lost to follow-up patients, 
postrandomisation exclusions and protocol violations. 
Sensitivity analyses considered the effect of temporary 
protocol deviations.
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Pairwise, sequential comparisons were made for CHG 
versus SP, and ISD versus SED. Baseline group compari-
sons were done by clinical parameters. Relative incidence 
rates of PICC failure per 100 devices and per 1000 PICC 
days (95% CIs) summarised treatment impact, with 
group differences tested. Kaplan-Meier survival curves 
(and log rank M-H test) compared failure rates over time. 
Secondary end points were compared between groups 
using parametric and non-parametric techniques. The 
proportional hazards assumption was checked, and Cox 
regression tested the effect of group, patient, device and 
clinical variables on outcomes, and assessed for an inter-
action effect. Regression models allowed for stratification 
factors and clustering by site (gamma-shared frailty).45 
Subgroup analysis tested for differences within and 
between hospital site including paediatric/adult; cancer 
diagnosis type and inpatient/outpatient status). p Values 
<0.05 were considered to be statistically significant.
estimating cost parameters
We hypothesised significantly reduced costs in both treat-
ments over controls from a direct hospital perspective for 
the episode of care (standardised AUD$, 2019 year). We 
quantified additional costs, benefits, net monetary benefit 
in the context of CABSI/PICC failure, re-insertions and 
the treatment costs of complications per group. Detailed 
resource use for PICC insertion/removal, plus dressing 
and securement application/removal was recorded for 
100 procedures selected at random (25 per group). Staff 
wage costs for application, troubleshooting, replace-
ment, consultation and equipment used were recorded. 
Direct observation of practice in response to CABSI or 
PICC failure informed total resource use and costs per 
group. Cost offsets due to reductions in adverse events 
were calculated on direct hospital costs, and for length of 
stay.  Analysis with analysis of covariance compared mean 
costs per group.
Qualitative data collection and analysis
The following qualitative data complemented the trial 
results and informed translation:
1. Brief semi-structured interviews (approximately 10 
per group, spread across sites) with patients/parents 
about their experience of study products, the trial 
and suggested improvements.53 The final sample 
was determined by data saturation. Interviews were 
audiotaped, transcribed and thematically analysed 
based on Norwood’s framework and an inductive 
process.54
2. ReNs documented field notes related to positive or 
negative trial or study product feedback offered by 
any patient/parents or practitioners. Analysis was 
thematic as above.
3. We videorecorded approximately five episodes per 
group of study product use (including application, 
replacement and removal), with brief semi-structured 
interviews with the clinicians about the procedure. 
Final sample size was determined by data saturation, 
with data transcription and thematic analysis as above. 
Video data assessed procedural time and resource 
use (to inform health economic analysis), product 
usability and integrity of protocol delivery.
4. An Evidence Users’ Reference Group was established in the 
final year including investigators, patients/parents, 
nursing and medical clinicians from cancer, infection 
control, infectious diseases, radiology, vascular access 
and policy makers. The Group reflected on trial results 
and qualitative data from 1 to 3 above, identified 
likely barriers and enablers of implementation 
and developed an evidence use plan with tools and 
strategies.55 56
eThIcs and dIsseMInaTIon of resulTs
The trial had approval from the Children’s Health 
Queensland Hospital and Health Service Human 
Research Ethics Committee (HREC) HREC/15/
QRCH/241, and Griffith University HREC Ref. No. 
2016/063. Minor adverse events (eg, skin reaction to 
dressing) were treated as per usual practice with no cost 
to patients. Clinical trial insurance was held by the Griffith 
University. Written informed consent to participate was 
obtained from participants or representatives, including 
an additional option to store specimens and data for 
future research. Consent could be later withdrawn. Iden-
tifying details were kept confidential via assigned numeric 
study IDs. Serious adverse events were monitored and 
reported to the HREC as were any important protocol 
modifications. If important protocol amendments were 
made (eg, changes to eligibility criteria), CMR updated 
all investigators, HRECs, updated patient information 
and consent forms and updated the trial registry. A Data 
Safety Monitoring Committee reviewed blinded interim 
data and adverse events at n=400 and 800 to advise on 
safety. Before qualitative interviews and video record-
ings, participants provided written informed consent. If 
patients/parents became distressed, they received initial 
support from the experienced qualitative reviewers and 
were referred to the relevant institutional contact. The 
trial and substudies were written by the investigators and 
published in peer-reviewed journals, consistent with the 
International Committee of Medical Journal Editors 
(ICMJE) Guidelines and authorship criteria.
dIscussIon
PICC failure is unacceptably high in patients with cancer. 
CABSI has significant related morbidity and increases 
the risk of death almost threefold.12 13 57 PICC failure in 
all its forms (eg, dislodgement) wastes millions of health 
dollars annually through increased procedures, treat-
ment of complications and extended hospital days. All 
PICC failure results in negative patient-related outcomes, 
including increased pain and anxiety; delays in treatment 
and unnecessary exposure to the risks associated with 
repeated reinsertions. Older dressing and securement 
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methods likely contribute to PICC failure, but there is 
inadequate data to resolve uncertainty about their efficacy 
or safety compared with newer alternatives. At present, 
practitioners and policy makers make decisions with 
uncertainty, due to lack of adequate evidence. This prag-
matic, multicentre, factorial, superiority RCT will help to 
resolve uncertainty and inform international policy and 
practice.
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